NCT02274233View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Iron OverloadBeta-Thalassemia
Interventions
DRUG

SP-420

Trial Locations (7)

10065

Sideris Investigative Site, New York

10700

Sideris Investigative Site, Bangkok

19104

Sideris Investigative Site, Philadelphia

35100

Sideris Investigative Site, Izmir

02115

Sideris Investigative Site, Boston

M5G 2N2

Sideris Investigative Site, Toronto

Unknown

Sideris Investigative Site, Beirut

Sponsors
All Listed Sponsors
lead

Sideris Pharmaceuticals

INDUSTRY

NCT02274233 - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia | Biotech Hunter | Biotech Hunter